

**ANNUAL DECLARATION OF COMPLIANCE
PURSUANT TO CALIFORNIA HEALTH AND SAFETY CODE §§ 119400 – 119402**

Consistent with the Department of Health and Human Services Office of the Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, Tandem Diabetes Care, Inc. (“Tandem”) has adopted a Comprehensive Compliance Program and tailored it to the nature of its business as a medical device manufacturer. While the California Health and Safety Code, Division 104, Part 15, Chapter 8, Sections 119400-119402 (the “Statute”) makes reference to compliance with the Pharmaceutical Research and Manufacturers of America’s Code on Interactions with Healthcare Professionals (“PhRMA Code”), we manufacture medical devices rather than pharmaceutical products. Therefore, we determined that it was more appropriate for the company to instead adopt policies and procedures consistent with the AdvaMed Code of Ethics on Interactions with Health Care Professionals, which although substantially similar to the PhRMA Code, recognizes significant differences applicable to the medical device industry.

As of the date of this compliance disclosure, to our knowledge, Tandem is in compliance with its Comprehensive Compliance Program and the requirements of the Statute, as in effect on June 30, 2017, based on our good faith understanding of the requirements of the Statute as it may apply to medical device manufacturers. In conjunction with this declaration, please note that, from time to time, we may identify potential or actual violations of provisions of our compliance program. In those instances, we promptly investigate and respond appropriately to any alleged noncompliance or misconduct in a timely manner.

Dated: July 1, 2017

**STATE OF CALIFORNIA
COMPREHENSIVE COMPLIANCE PROGRAM**

Adopted in accordance with California law, this Comprehensive Compliance Program (“Compliance Program”), reflects the commitment of Tandem Diabetes Care, Inc. (“Tandem” or “Company”) to ethical and responsible decision-making in the sale and marketing of Company products. Tandem believes that adherence to applicable laws, regulations, and industry standards is critical to the Company’s operations and success. The Compliance Program is designed to prevent and detect violations of applicable law, compliance standards, and other Company policies.

WRITTEN STANDARDS

Tandem has adopted a written policy on interactions with Healthcare Professionals (the “HCP Policy”). The principles in the HCP Policy are based on legal requirements and applicable guidance, including industry guidance (e.g., the AdvaMed Code of Ethics on Interactions with Health Care Professionals) and guidance from the U.S. Department of Health & Human Services Office of Inspector General. The term "Healthcare Professionals" includes those individuals or entities involved in the provision of health care services and/or items to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Company products.

In response to California Health and Safety Code, Division 104, Part 15, Chapter 8, Sections 119400-119402 (the "Statute"), Tandem has established an annual, per individual limit on gifts, promotional materials, or items or activities that it may give or otherwise provide to an individual Healthcare Professional of \$2,500, but note that our policies currently prohibit the provision of gifts or entertainment or recreational activities to any Healthcare Professional and so we expect that any educational items, product literature and related items will be well below such limitation. Consistent with the Statute, this dollar limit does not include any (a) product samples of our medical devices intended for free distribution to patients we may provide to hospitals and other medical institutions or Healthcare Professionals (including products used for demonstration or training purposes), (b) financial support we may provide for continuing medical education forums, (c) financial support we may provide for health educational scholarships, or (d) payments we may make for legitimate professional services provided by a Healthcare Professional. Consistent with the AdvaMed Code, this dollar limit also does not include plant visits to observe our quality production facilities, training on the safe and effective uses of our medical devices consistent with approved uses, which for many products is required by the U.S. Food and Drug Administration and/or to help health care providers provide better patient care or patients to properly use our products, or any grants made to support research, fellowship programs and/or charitable initiatives of a Healthcare Professional.

COMPLIANCE OFFICER AND COMPLIANCE COMMITTEE

Tandem's General Counsel currently also serves as the Company's Compliance Officer. In that capacity, he has direct access to Tandem's Board of Directors (the "Board") and to the Board's Nominating and Corporate Governance Committee. Tandem's Compliance Officer is responsible for providing interpretive guidance in applying the HCP Policy and related policies to specific situations and for generally overseeing implementation and enforcement of the Compliance Program. The Compliance Officer and/or his designee(s) conduct and/or monitor investigations into alleged violations of law and/or Company policies or procedures, including the Company's Code of Business Ethics for Employees and Directors, and the HCP Policy. As a result of these investigations, the Compliance Officer, together with representatives of the Company's human resources department and others as appropriate, determines appropriate corrective, preventative and/or disciplinary actions to be taken and monitors to ensure that such actions are taken.

TRAINING & EDUCATION

Tandem recognizes that training and education are key parts of an effective compliance program. Employees who interact directly or indirectly with Healthcare Professionals receive training on Tandem's HCP Policy. Additional ethics and compliance education and training programs are provided on an ongoing basis as required by an individual's job responsibilities and by changes in the laws and Company policies and procedures. Training records are maintained in accordance with Company policy.

REPORTING VIOLATIONS OF THE COMPLIANCE PROGRAM

The Compliance Officer is responsible for establishing and maintaining Tandem's confidential reporting system, including a toll-free, 24-7 telephone service which allows employees, customers, suppliers and others to ask questions in a confidential manner about ethical or compliance issues or to report possible violations of applicable law or Company policies or procedures, without fear of retaliation, and anonymously if so desired.

Employees may also ask questions of, or report concerns to, supervisors and other members of management. There will be no retaliation against anyone who has reported a suspected violation or concern in good faith. The Company encourages anyone who reports information to identify themselves when making such a report in order to facilitate investigation of the possible violations (subject to compliance with local laws), but reports may also be made anonymously.

CORRECTIVE OR PREVENTIVE ACTION

The Compliance Program is designed to prevent and detect conduct that may be inconsistent with the requirements of applicable law or regulations or the HCP Policy. If improper conduct is detected, Tandem will address it promptly and responsibly with corrective action including, but not limited to, appropriate disciplinary measures. The Company will assess whether violations of the Compliance Program, including the HCP Policy, are a result of gaps in policies, practices, training, internal controls or individual acts, and will take action to prevent future violations.

MONITORING AND PERIODIC REVIEW

The Compliance Officer and/or the Compliance Officer's designee(s) will monitor the implementation and administration of the Compliance Program, including monitoring the activities of sales and marketing personnel. As part of that oversight, the Compliance Officer and/or his designee(s) will review Company operations and industry developments, to identify new and emerging risk factors for the Company in its relationships with Healthcare Professionals.

COPIES OF COMPLIANCE PROGRAM AND ANNUAL DECLARATION

Copies of this declaration and the Comprehensive Compliance Program may be obtained by calling 1-877-801-6901 or from our website at <http://investor.tandemdiabetes.com/governance.cfm>.

Effective Date: July 1, 2014